Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Antibody drug conjugates industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Product type trends
2.1.4 Technology trends
2.1.5 Application trends
2.1.6 Target type trends
Chapter 3 Antibody Drug Conjugates Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of cancer globally
3.2.1.2 Growing demand for antibody-based cancer therapies
3.2.1.3 Increasing advancements in antibody technology
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory approval
3.2.2.2 High manufacturing costs of antibody drug conjugates
3.3 Growth potential analysis
3.3.1 By product type
3.3.2 By technology
3.3.3 By application
3.3.4 By target type
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6 Application potential
3.7 Technology landscape
3.8 Pipeline analysis
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Licensing, merger & acquisition landscape
4.3 Venture capital funding events and IPOs
4.4 Company matrix analysis, 2022
4.5 Competitive analysis of major market players
4.6 Competitive positioning matrix
4.7 Strategy dashboard
4.8 Strategy outlook matrix
Chapter 5 Antibody Drug Conjugates Market Size and Forecast, By Product Type (USD Million)
5.1 Key trends, by product type
5.2 Adcetris
5.3 Perjeta
5.4 Kadcyla
5.5 Other product type
Chapter 6 Antibody Drug Conjugates Market Size and Forecast, By Technology (USD Million)
6.1 Key trends, by technology
6.2 Cleavable linker
6.3 Non-cleavable linker
6.4 Linkerless
Chapter 7 Antibody Drug Conjugates Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Blood cancer
7.3 Breast cancer
7.4 Ovary cancer
7.5 Lung cancer
7.6 Other applications
Chapter 8 Antibody Drug Conjugates Market Size and Forecast, By Target Type (USD Million)
8.1 Key trends, by target type
8.2 CD30 antibodies
8.3 HER2 antibodies
8.4 Other target type
Chapter 9 Antibody Drug Conjugates Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of MEA
Chapter 10 Company Profiles
10.1 Seagen Inc.
10.2 Pfizer Inc.
10.3 Sorrento Therapeutics Inc.
10.4 F. Hoffmann-La Roche Ltd
10.5 Oxford BioTherapeutics Ltd
10.6 ImmunoGen Inc.
10.7 Mersana Therapeutics Inc.
10.8 AbbVie Inc.
10.9 Takeda Pharmaceutical Company Ltd
10.10 ADC Therapeutics SA
10.11 AstraZeneca plc
10.12 Astellas Pharma Inc
10.13 GlaxoSmithKline plc
